{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:45:54Z","timestamp":1785321954110,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jtho.2021.01.1619","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T11:50:50Z","timestamp":1613389850000},"page":"798-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-5202","authenticated-orcid":false,"given":"Teodora","family":"Radonic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.R.R.","family":"Geurts-Giele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris G.","family":"Samsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido M.J. M.","family":"Roemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Thunnissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle C.","family":"Meijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein F.B. M.","family":"Sleddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winand N.M.","family":"Dinjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C.","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Weijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst Jan M.","family":"Speel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Wezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Monkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roepman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Dubbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.01.1619_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A\u00a0transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2021.01.1619_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmoldx.2013.11.007","article-title":"A\u00a0single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer","volume":"16","author":"Lira","year":"2014","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtho.2021.01.1619_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000336975","article-title":"Thyroid cancer: role of RET and beyond","volume":"1","author":"Carlomagno","year":"2012","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.jtho.2021.01.1619_bib4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JTO.0000000000000135","article-title":"Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma","volume":"9","author":"Mizukami","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2014.02.007","article-title":"ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features","volume":"84","author":"Pan","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.01.1619_bib6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/modpathol.2014.107","article-title":"Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma","volume":"28","author":"Lee","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib7","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014"},{"key":"10.1016\/j.jtho.2021.01.1619_bib8","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2020.02.006","article-title":"Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: a multicenter retrospective study","volume":"21","author":"Shen","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2021.01.1619_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12885-015-1146-8","article-title":"A\u00a0retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized phase III studies","volume":"15","author":"Platt","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2021.01.1619_bib10","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2021.01.1619_bib11","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jtho.2019.08.059","article-title":"PL02.08 registrational results of LIBRETTO-001: a phase 1\/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers","volume":"14","author":"Drilon","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib12","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib13","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.01.1619_bib15","doi-asserted-by":"crossref","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2021.01.1619_bib16","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib17","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2020-052","article-title":"FDA approves selpercatinib; pralsetinib may soon follow","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2021.01.1619_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2015.06.021","article-title":"Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI","volume":"89","author":"Klempner","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.01.1619_bib19","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1002\/cam4.2599","article-title":"Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?","volume":"8","author":"Tachon","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2021.01.1619_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1677\/jme.1.01755","article-title":"Quantitative real-time RT-PCR - a perspective","volume":"34","author":"Bustin","year":"2005","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jmoldx.2018.10.003","article-title":"Design, optimization, and multisite evaluation of a targeted next-generation sequencing assay system for chimeric RNAs from gene fusions and exon-skipping events in non\u2013small cell lung cancer","volume":"21","author":"Blidner","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtho.2021.01.1619_bib22","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.onc.1210843","article-title":"Complex patterns of ETS gene alteration arise during cancer development in the human prostate","volume":"27","author":"Clark","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2021.01.1619_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","article-title":"Testing for ROS1 in non-small cell lung cancer: a review with recommendations","volume":"469","author":"Bubendorf","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2021.01.1619_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","article-title":"Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European thoracic oncology platform Lungscape project","volume":"13","author":"Letovanec","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2021.01.1619_bib26","doi-asserted-by":"crossref","unstructured":"Cameron D, Baber J, Shale C, et\u00a0al. GRIDSS, PURPLE, LINX: unscrambling the tumor genome via integrated analysis of structural variation and copy number. https:\/\/www.biorxiv.org\/content\/10.1101\/781013v1.full.pdf. Accessed November 26, 2020.","DOI":"10.1101\/781013"},{"key":"10.1016\/j.jtho.2021.01.1619_bib27","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.01.1619_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.07.009","article-title":"Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma","volume":"82","author":"Go","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.01.1619_bib29","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.01.1619_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JTO.0000000000000444","article-title":"ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice","volume":"10","author":"Martin","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib31","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jtho.2018.05.041","article-title":"Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples","volume":"13","author":"Davies","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-012-1281-4","article-title":"EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations","volume":"461","author":"Thunnissen","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2021.01.1619_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cam4.13","article-title":"RET expression and detection of KIF5B\/RET gene rearrangements in Japanese lung cancer","volume":"1","author":"Sasaki","year":"2012","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2021.01.1619_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-60761-789-1_1","article-title":"Fluorescence in situ hybridization (FISH), basic principles and methodology","volume":"659","author":"Garimberti","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib35","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.01.1619_bib36","article-title":"Key considerations for comprehensive validation of an RNA fusion NGS panel","volume":"21","author":"Barua","year":"2020","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.jtho.2021.01.1619_bib37","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2021.01.1619_bib38","doi-asserted-by":"crossref","first-page":"170007","DOI":"10.1183\/16000617.0007-2017","article-title":"Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens","volume":"26","author":"Bubendorf","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jtho.2021.01.1619_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.yexmp.2011.09.013","article-title":"Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA\/RNA extraction techniques","volume":"92","author":"Turashvili","year":"2012","journal-title":"Exp Mol Pathol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642101666X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642101666X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:46:47Z","timestamp":1761562007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608642101666X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S155608642101666X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.01.1619","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.01.1619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}